City

Scottsdale (1)

Shanghai (1)

Condition

Invasive Duct Carcinoma of Breast (2)

Breast Cancer (1)

DCIS (1)

Mucinous Breast Cancer (1)

Tubular Breast Cancer (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1/phase 2 (1)

phase 3 (1)

Sponsor

Integro Theranostics (1)

RenJi Hospital (1)

Collaborator

Intervention

ec to docetaxel or paclitaxel (1)

ls301-it 0.025 mg/kg (1)

ls301-it 0.05 mg/kg (1)

ls301-it 0.075 mg/kg (1)

ls301-it 0.1 mg/kg (1)

paclitaxel, cisplatin (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

invasive duct carcinoma of breast

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast Trial in Scottsdale (LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT

Not yet recruiting

Breast Cancer
+2 more

LS301-IT 0.025 mg/kg
+3 more

Scottsdale, Arizona

Integro Theranostics Research Site #1

Jun 2, 2023

Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast Trial in Shanghai (Paclitaxel, Cisplatin, EC to

Recruiting

Tubular Breast Cancer
+2 more

Paclitaxel, Cisplatin
EC to docetaxel or paclitaxel

Shanghai, Shanghai, China

Renji Hospital, School of Medicine, Shanghai Jiaotong University

Sep 21, 2021